Research ArticleArticle
Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients
Jérémy Clément, Pierre Duffau, Joel Constans, Thierry Schaeverbeke, Jean-Francois Viallard, Damien Barcat, Jean-Philippe Vernhes, Laurent Sailler and Fabrice Bonnet
The Journal of Rheumatology February 2021, jrheum.200952; DOI: https://doi.org/10.3899/jrheum.200952
Jérémy Clément
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Pierre Duffau
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Joel Constans
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Thierry Schaeverbeke
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Jean-Francois Viallard
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Damien Barcat
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Jean-Philippe Vernhes
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Laurent Sailler
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
Fabrice Bonnet
J. Cl é ment, MD, Bordeaux University Hospital, Department of Internal Medicine and Infectious Diseases, Bordeaux; P. Duffau, MD, PhD, Bordeaux University Hospital, Internal Medicine Department, Bordeaux; J. Constans, MD, PhD, Bordeaux University Hospital, Vascular Medicine Department, Saint-Andr Hospital, Bordeaux; T. Schaeverbeke, MD, PhD, Bordeaux University Hospital, Department of Rheumatology, Bordeaux; JF Viallard, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Haut-L é v ê que, Pessac; D. Barcat, MD, CH de Libourne, Department of Internal Medicine, Libourne; JP Vernhes, MD, CH of Libourne, Department of Rheumatology, Libourne; L. Sailler, MD, PhD, Toulouse University Hospital, Department of Internal Medicine, Toulouse; F. Bonnet, MD, PhD, CHU de Bordeaux, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, Bordeaux, and Universit é de Bordeaux, INSERM U1219, Bordeaux Population Health Research Center, Bordeaux, France. The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Service de M é decine Interne and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021. break /> The authors declare no conflicts of interest. Address correspondence to Dr. F. Bonnet, Department of Internal Medicine and Infectious Diseases, H ô pital Saint-Andr é, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France. Email: fabrice.bonnet@chu-bordeaux.fr. Accepted for publication January 26, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients
Jérémy Clément, Pierre Duffau, Joel Constans, Thierry Schaeverbeke, Jean-Francois Viallard, Damien Barcat, Jean-Philippe Vernhes, Laurent Sailler, Fabrice Bonnet
The Journal of Rheumatology Feb 2021, jrheum.200952; DOI: 10.3899/jrheum.200952
Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients
Jérémy Clément, Pierre Duffau, Joel Constans, Thierry Schaeverbeke, Jean-Francois Viallard, Damien Barcat, Jean-Philippe Vernhes, Laurent Sailler, Fabrice Bonnet
The Journal of Rheumatology Feb 2021, jrheum.200952; DOI: 10.3899/jrheum.200952